Pierre Dubois, Paul-Henri Moisson, and Jean Tirole, “The Economics of Transferable Patent Extensions”, TSE Working Paper, n. 22-1377, November 2022, revised December 2022.
Pierre Dubois, and Gosia Majewska, “Mergers and Advertising in the Pharmaceutical Industry”, TSE Working Paper, n. 22-1380, October 2022, revised February 2025.
James K. Hammitt, “Downside Risk Aversion vs Decreasing Absolute Risk Aversion: An Intuitive Exposition”, TSE Working Paper, n. 22-1359, September 2022.
Tuba Tuncel, “Should We Prevent Off-Label Drug Prescriptions? Empirical Evidence from France”, TSE Working Paper, n. 22-1383, September 2022.
Chiara Canta, and Helmuth Cremer, “Family bargaining and the gender gap in informal care”, TSE Working Paper, n. 2022-1352, August 2022.
Philippe De Donder, Marie-Louise Leroux, and François Salanié, “Advantageous selection without moral hazard”, TSE Working Paper, n. 22-1334, May 2022, revised April 25, 2023.
Daniel Herrera-Araujo, Christoph Rheinberger, and James K. Hammitt, “Valuing non-marginal changes in mortality and morbidity risk”, TSE Working Paper, n. 22-1331, April 2022.
Pierre Dubois, Ashvin Gandhi, and Shoshana Vasserman, “Bargaining and International Reference Pricing in the Pharmaceutical Industry”, TSE Working Paper, n. 22-1338, April 2022.
Renato Gomes, Jean-Marie Lozachmeur, and Lucas Maestri, “Nonlinear Pricing in Oligopoly: How Brand Preferences Shape Market Outcomes”, TSE Working Paper, n. 22-1326, March 2022.